Oncolytic virotherapy for pancreatic cancer

Sonia Wennier; Shoudong Li; Grant McFadden

doi:10.1017/S1462399411001876

Oncolytic virotherapy for pancreatic cancer

Published online by Cambridge University Press: 18 May 2011

Sonia Wennier ,

Shoudong Li and

Grant McFadden

Show author details

Sonia Wennier: Affiliation:
Molecular Genetics and Microbiology Department, University of Florida, Gainesville, USA
Shoudong Li: Affiliation:
Molecular Genetics and Microbiology Department, University of Florida, Gainesville, USA
Grant McFadden*: Affiliation:
Molecular Genetics and Microbiology Department, University of Florida, Gainesville, USA
*: *Corresponding author: Grant McFadden, University of Florida, 1600 SW Archer Road, PO Box 100266, Gainesville, FL 32610, USA. E-mail: [email protected]

Article contents

Abstract
References

Get access

Rights & Permissions

Abstract

Within the past decade, many oncolytic viruses (OVs) have been studied as potential treatments for pancreatic cancer and some of these are currently under clinical trials. The applicability of certain OVs, such as adenoviruses, herpesviruses and reoviruses, for the treatment of pancreatic cancer has been intensively studied for several years, whereas the applicability of other more recently investigated OVs, such as poxviruses and parvoviruses, is only starting to be determined. At the same time, studies have identified key characteristics of pancreatic cancer biology that provide a better understanding of the important factors or pathways involved in this disease. This review aims to summarise the different replication-competent OVs proposed as therapeutics for pancreatic cancer. It also focuses on the unique biology of these viruses that makes them exciting candidate virotherapies for pancreatic cancer and discusses how they could be genetically manipulated or combined with other drugs to improve their efficacy based on what is currently known about the molecular biology of pancreatic cancer.

Type: Review Article
Information: Expert Reviews in Molecular Medicine , Volume 13 , March 2011 , e18

DOI: https://doi.org/10.1017/S1462399411001876 [Opens in a new window]
Copyright: Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Jemal, A. et al. (2010) Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 60, 277-300Google Scholar PubMed

2Basturk, O., Coban, I. and Adsay, N.V. (2010) Biological classification and biological behavior of pancreatic neoplasia. In Pancreatic Cancer (Neoptolemos, J.P., Urrutia, R., Abbruzzese, J. and Buchler, M., eds), pp. 40-70. Springer Science and Business Media, New YorkGoogle Scholar

3Rozenblum, E. et al. (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Research 57, 1731-1734Google Scholar PubMed

4Almoguera, C. et al. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549-554CrossRef Google Scholar PubMed

5Adjei, A.A. (2001) Blocking oncogenic Ras signaling for cancer therapy. Journal of the National Cancer Institute 93, 1062-1074CrossRef Google Scholar PubMed

6Grippo, P.J. et al. (2003) Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice. Cancer Research 63, 2016-2019Google Scholar PubMed

7Aguirre, A.J. et al. (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes and Development 17, 3112-3126CrossRef Google Scholar PubMed

8Bardeesy, N. et al. (2006) Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proceedings of the National Academy of Sciences of the United States of America 103, 5947-5952CrossRef Google Scholar PubMed

9Jones, S. et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806CrossRef Google Scholar PubMed

10Chu, G.C. et al. (2007) Stromal biology of pancreatic cancer. Journal of Cellular Biochemistry 101, 887-907CrossRef Google Scholar PubMed

11Olive, K.P. et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461CrossRef Google Scholar

12Shah, A.N. et al. (2007) Development and characterization of gemcitabine-resistant pancreatic tumor cells. Annals of the Surgical Oncology 14, 3629-3637CrossRef Google Scholar PubMed

13Wang, Z. et al. (2009) Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Research 69, 2400-2407CrossRef Google Scholar PubMed

14Thiery, J.P. et al. (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890CrossRef Google Scholar PubMed

15Joo, Y.E. et al. (2002) Expression of E-cadherin, alpha- and beta-catenins in patients with pancreatic adenocarcinoma. Pancreatology 2, 129-137CrossRef Google Scholar PubMed

16Nakajima, S. et al. (2004) N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clinical Cancer Research 10(12 Pt 1), 4125-4133CrossRef Google Scholar PubMed

17Arumugam, T. et al. (2009) Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Research 69, 5820-5828CrossRef Google Scholar PubMed

18Burris, H.A. III, et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology 15, 2403-2413CrossRef Google Scholar PubMed

19Hertel, L.W. et al. (1990) Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Research 50, 4417-4422Google Scholar

20Huang, P. et al. (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Research 51, 6110-6117Google Scholar PubMed

21Colucci, G. et al. (2002) Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94, 902-910CrossRef Google Scholar PubMed

22Louvet, C. et al. (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. Journal of Clinical Oncology 23, 3509-3516CrossRef Google Scholar PubMed

23Rocha Lima, C.M. et al. (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. Journal of Clinical Oncology 22, 3776-3783CrossRef Google Scholar PubMed

24Kulke, M.H. et al. (2009) Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. Journal of Clinical Oncology 27, 5506-5512CrossRef Google Scholar PubMed

25Rocha-Lima, C.M. and Raez, L.E. (2009) Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. Pharmacy and Therapeutics 34, 554-564Google Scholar PubMed

26Moore, M.J. et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 25, 1960-1966CrossRef Google Scholar PubMed

27Conroy, T. et al. (2005) Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer – a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. Journal of Clinical Oncology 23, 1228-1236CrossRef Google Scholar PubMed

28Kim, R. (2010) FOLFIRINOX: a new standard treatment for advanced pancreatic cancer? Lancet Oncology 12, 8-9CrossRef Google Scholar PubMed

29Plentz, R.R., Manns, M.P. and Greten, T.F. (2010) Molecular therapy of pancreatic cancer. Minerva Endocrinologica 35, 27-33Google Scholar PubMed

30Mackenzie, R.P. and McCollum, A.D. (2009) Novel agents for the treatment of adenocarcinoma of the pancreas. Expert Review of Anticancer Therapy 9, 1473-1485CrossRef Google Scholar PubMed

31Davis, J.J. and Fang, B. (2005) Oncolytic virotherapy for cancer treatment: challenges and solutions. Journal of Gene Medicine 7, 1380-1389CrossRef Google Scholar PubMed

32Vaha-Koskela, M.J., Heikkila, J.E. and Hinkkanen, A.E. (2007) Oncolytic viruses in cancer therapy. Cancer Letters 254, 178-216CrossRef Google Scholar PubMed

33Bischoff, J.R. et al. (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376CrossRef Google Scholar PubMed

34O'Shea, C.C. et al. (2004) Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6, 611-623CrossRef Google Scholar PubMed

35Heise, C. et al. (2000) An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nature Medicine 6, 1134-1139CrossRef Google Scholar PubMed

36Fueyo, J. et al. (2000) A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2-12CrossRef Google Scholar PubMed

37Leitner, S. et al. (2009) Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clinical Cancer Research 15, 1730-1740CrossRef Google Scholar PubMed

38Yoon, S.S. et al. (1998) Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Annals of Surgery 228, 366-374CrossRef Google Scholar PubMed

39Smith, K.D. et al. (2006) Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. Journal of Virology 80, 1110-1120CrossRef Google Scholar

40Sarinella, F. et al. (2006) Oncolysis of pancreatic tumour cells by a gamma34.5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway. Gene Therapy 13, 1080-1087CrossRef Google Scholar

41Smith, C.C. et al. (2000) Ras-GAP binding and phosphorylation by herpes simplex virus type 2 RR1 PK (ICP10) and activation of the Ras/MEK/MAPK mitogenic pathway are required for timely onset of virus growth. Journal of Virology 74, 10417-10429CrossRef Google Scholar PubMed

42Rommelaere, J. et al. (2010) Oncolytic parvoviruses as cancer therapeutics. Cytokine and Growth Factor Reviews 21, 185-195CrossRef Google Scholar PubMed

43Dempe, S. et al. (2010) SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV. International Journal of Cancer 126, 2914-2927CrossRef Google Scholar PubMed

44Riolobos, L. et al. (2010) Viral oncolysis that targets Raf-1 signaling control of nuclear transport. Journal of Virology 84, 2090-2099CrossRef Google Scholar PubMed

45Strong, J.E. et al. (1998) The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO Journal 17, 3351-3362CrossRef Google Scholar PubMed

46Thorne, S.H., Hwang, T.H. and Kirn, D.H. (2005) Vaccinia virus and oncolytic virotherapy of cancer. Current Opinion in Molecular Therapeutics 7, 359-365Google Scholar PubMed

47Kirn, D.H. and Thorne, S.H. (2009) Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nature Reviews. Cancer 9, 64-71CrossRef Google Scholar PubMed

48Wang, G. et al. (2006) Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proceedings of the National Academy of Sciences of the United States of America 103, 4640-4645CrossRef Google Scholar PubMed

49Kim, M. et al. (2010) The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. Oncogene 29, 3990-3996CrossRef Google Scholar PubMed

50Galanis, E. (2010) Therapeutic potential of oncolytic measles virus: promises and challenges. Clinical Pharmacology and Therapeutics 88, 620-625CrossRef Google Scholar

51Paraskevakou, G. et al. (2007) Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Molecular Therapy 15, 677-686CrossRef Google Scholar PubMed

52Kinoh, H. et al. (2009) Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies. Gene Therapy 16, 392-403CrossRef Google Scholar PubMed

53Spencer, J.F. et al. (2009) New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster. Cancer Gene Therapy 16, 912-922CrossRef Google Scholar PubMed

54O'Shea, C.C. et al. (2005) Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 8, 61-74CrossRef Google Scholar PubMed

55Heise, C. et al. (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Medicine 3, 639-645CrossRef Google Scholar PubMed

56Mymryk, J.S. (1996) Tumour suppressive properties of the adenovirus 5 E1A oncogene. Oncogene 13, 1581-1589Google Scholar PubMed

57Oberg, D. et al. (2010) Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clinical Cancer Research 16, 541-553CrossRef Google Scholar PubMed

58Kamphaus, G.D. et al. (2000) Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. Journal of Biological Chemistry 275, 1209-1215CrossRef Google Scholar PubMed

59Delesque, N. et al. (1997) sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Research 57, 956-962Google Scholar PubMed

60Zhang, Z. et al. (2009) Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer. Clinical Cancer Research 15, 5154-5160CrossRef Google Scholar PubMed

61Freytag, S.O. et al. (2007) Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Molecular Therapy 15, 1600-1606CrossRef Google Scholar

62Ramirez, P.J. et al. (2008) Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model. American Journal of Surgery 195, 481-490CrossRef Google Scholar

63Wang, H. et al. (2011) Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nature Medicine 17, 96-104CrossRef Google Scholar

64Nishimoto, T. et al. (2009) Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob. Gene Therapy 16, 669-680CrossRef Google Scholar PubMed

65Nelson, A.R. et al. (2009) Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer. Cancer Science 100, 2181-2187CrossRef Google Scholar PubMed

66Huch, M. et al. (2009) Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models. Neoplasia 11, 518-528, 4 p following 28CrossRef Google Scholar PubMed

67Onimaru, M. et al. (2010) hTERT-promoter-dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication-defective adenovirus vectors in pancreatic cancer cells. Cancer Science 101, 735-742CrossRef Google Scholar PubMed

68Bortolanza, S. et al. (2009) Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Molecular Therapy 17, 614-622CrossRef Google Scholar PubMed

69Molina, M.A. et al. (1999) Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Research 59, 4356-4362Google Scholar PubMed

70Mihaljevic, A.L. et al. (2010) Molecular mechanism of pancreatic cancer – -understanding proliferation, invasion, and metastasis. Langenbecks Arch Surg 395, 295-308CrossRef Google Scholar PubMed

71Onimaru, M. et al. (2010) Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer. Cancer Letters 294, 178-186CrossRef Google Scholar PubMed

72He, B., Gross, M. and Roizman, B. (1997) The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proceedings of the National Academy of Sciences of the United States of America 94, 843-848CrossRef Google Scholar PubMed

73Mundschau, L.J. and Faller, D.V. (1994) Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells. Biochimie 76, 792-800CrossRef Google Scholar PubMed

74Mineta, T. et al. (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Medicine 1, 938-943CrossRef Google Scholar PubMed

75Meignier, B., Longnecker, R. and Roizman, B. (1988) In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. Journal of Infectious Diseases 158, 602-614CrossRef Google Scholar PubMed

76Varghese, S. and Rabkin, S.D. (2002) Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Therapy 9, 967-978CrossRef Google Scholar PubMed

77Liu, B.L. et al. (2003) ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy 10, 292-303CrossRef Google Scholar PubMed

78Kimata, H. et al. (2003) Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses. Hepatogastroenterology 50, 961-966Google Scholar PubMed

79Kasuya, H. et al. (2007) Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy. Cancer Gene Therapy 14, 533-542CrossRef Google Scholar PubMed

80Fu, X. et al. (2006) Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Clinical Cancer Research 12, 3152-3157CrossRef Google Scholar PubMed

81Kasuya, H. et al. (1999) Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer. Journal of Surgical Oncology 72, 136-1413.0.CO;2-3>CrossRef Google Scholar PubMed

82Watanabe, I. et al. (2008) Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Cancer Chemotherapy and Pharmacology 61, 875-882CrossRef Google Scholar PubMed

83McAuliffe, P.F. et al. (2000) Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. Journal of Gastrointestinal Surgery 4, 580-588CrossRef Google Scholar PubMed

84Gil, Z. et al. (2007) Nerve-sparing therapy with oncolytic herpes virus for cancers with neural invasion. Clinical Cancer Research 13, 6479-6485CrossRef Google Scholar PubMed

85Simpson, G.R. et al. (2006) Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Research 66, 4835-4842CrossRef Google Scholar PubMed

86Shaughnessy, E. et al. (1996) Parvoviral vectors for the gene therapy of cancer. Seminars in Oncology 23, 159-171Google Scholar PubMed

87Angelova, A.L. et al. (2009) Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clinical Cancer Research 15, 511-519CrossRef Google Scholar PubMed

88Bhat, R. et al. (2011) Enhancement of NK cell anti-tumour responses using an oncolytic parvovirus. International Journal of Cancer 128, 908-919CrossRef Google Scholar

89Grekova, S. et al. (2010) Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent. Cancer Biology and Therapy 10, 52-61CrossRef Google Scholar PubMed

90Etoh, T. et al. (2003) Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clinical Cancer Research 9, 1218-1223Google Scholar PubMed

91Himeno, Y. et al. (2005) Efficacy of oncolytic reovirus against liver metastasis from pancreatic cancer in immunocompetent models. International Journal of Oncology 27, 901-906Google Scholar PubMed

92Hirano, S. et al. (2009) Reovirus inhibits the peritoneal dissemination of pancreatic cancer cells in an immunocompetent animal model. Oncology Reports 21, 1381-1384CrossRef Google Scholar

93Evgin, L. et al. (2010) Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. Molecular Therapy 18, 896-902CrossRef Google Scholar PubMed

94Kaufman, H.L. et al. (2007) Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. Journal of Translational Medicine 5, 60CrossRef Google Scholar PubMed

95Petrulio, C.A. and Kaufman, H.L. (2006) Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Reviews of Vaccines 5, 9-19CrossRef Google Scholar PubMed

96Kantor, J. et al. (1992) Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. Journal of the National Cancer Institute 84, 1084-1091CrossRef Google Scholar PubMed

97Yu, Y.A. et al. (2009) Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Molecular Cancer Therapeutics 8, 141-151CrossRef Google Scholar PubMed

98Hiley, C.T. et al. (2010) Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours. Gene Therapy 17, 281-287CrossRef Google Scholar PubMed

99Tysome, J.R. et al. (2009) Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Therapy 16, 1223-1233CrossRef Google Scholar PubMed

100Sypula, J. et al. (2004) Myxoma virus tropism in human tumor cells. Gene Therapy and Molecular Biology 8, 103-114Google Scholar

101Lun, X.Q. et al. (2007) Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Research 67, 8818-8827CrossRef Google Scholar PubMed

102Stanford, M.M. et al. (2008) Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Molecular Therapy 16, 52-59CrossRef Google Scholar PubMed

103Wu, Y. et al. (2008) Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clinical Cancer Research 14, 1218-1227CrossRef Google Scholar PubMed

104Lun, X. et al. (2005) Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Research 65, 9982-9990CrossRef Google Scholar PubMed

105Woo, Y. et al. (2008) Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Annals of the Surgical Oncology 15, 2329-2335CrossRef Google Scholar PubMed

106Radecke, F. et al. (1995) Rescue of measles viruses from cloned DNA. EMBO Journal 14, 5773-5784CrossRef Google Scholar PubMed

107Carlson, S.K. et al. (2009) Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. AJR. American Journal of Roentgenology 192, 279-287CrossRef Google Scholar PubMed

108Yu, W. and Fang, H. (2007) Clinical trials with oncolytic adenovirus in China. Current Cancer Drug Targets 7, 141-148CrossRef Google Scholar PubMed

109Mulvihill, S. et al. (2001) Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Therapy 8, 308-315CrossRef Google Scholar PubMed

110Hecht, J.R. et al. (2003) A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clinical Cancer Research 9, 555-561Google Scholar PubMed

111Nakao, A. et al. (2011) A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Therapy 18, 167-175CrossRef Google Scholar PubMed

112Forsyth, P. et al. (2008) A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Molecular Therapy 16, 627-632CrossRef Google Scholar PubMed

113Vidal, L. et al. (2008) A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clinical Cancer Research 14, 7127-7137CrossRef Google Scholar PubMed

114White, C.L. et al. (2008) Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Therapy 15, 911-920CrossRef Google Scholar PubMed

115Harrington, K.J. et al. (2010) Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine and Growth Factor Reviews 21, 91-98CrossRef Google Scholar PubMed

116Worschech, A. et al. (2009) The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunology and Immunotherapy 58, 1355-1362CrossRef Google Scholar PubMed

117Boisgerault, N., Tangy, F. and Gregoire, M. (2010) New perspectives in cancer virotherapy: bringing the immune system into play. Immunotherapy 2, 185-199CrossRef Google Scholar PubMed

Article contents

Oncolytic virotherapy for pancreatic cancer

Abstract

Access options

References

References

Further reading, resources and contacts

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

Article contents

Oncolytic virotherapy for pancreatic cancer

Abstract

Access options

References

References

Further reading, resources and contacts

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests